Evinacumab in Patients with Refractory Hypercholesterolemia
- 10 December 2020
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 383 (24), 2307-2319
- https://doi.org/10.1056/nejmoa2031049
Abstract
Patients with refractory hypercholesterolemia, who have high low-density lipoprotein (LDL) cholesterol levels despite treatment with lipid-lowering therapies at maximum tolerated doses, have an increased risk of atherosclerosis. In such patients, the efficacy and safety of subcutaneous and intravenous evinacumab, a fully human monoclonal antibody against angiopoietin-like 3, are not known.Keywords
Funding Information
- Regeneron Pharmaceuticals
This publication has 42 references indexed in Scilit:
- 2016 ESC/EAS Guidelines for the Management of DyslipidaemiasAtherosclerosis, 2016
- Systematic Review of Low‐Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial HypercholesterolemiaJournal of the American Heart Association, 2016
- Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe HypercholesterolemiaJournal of the American College of Cardiology, 2016
- The role of ANGPTL3 in controlling lipoprotein metabolismEndocrine, 2016
- The Agenda for Familial HypercholesterolemiaCirculation, 2015
- ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeysJournal of Lipid Research, 2015
- PCSK9 inhibition to reduce cardiovascular disease riskCurrent Opinion in Endocrinology, Diabetes and Obesity, 2015
- Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis SocietyEuropean Heart Journal, 2013
- Exome Sequencing,ANGPTL3Mutations, and Familial Combined HypolipidemiaThe New England Journal of Medicine, 2010
- Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative UltracentrifugeClinical Chemistry, 1972